- Research Article
- 10.1016/j.iac.2026.01.005
Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, and Anaphylaxis.
- Mar 01, 2026
- Immunology and allergy clinics of North America
- Anne K Ellis + 1 more +1
Publications from 2021 to 2026
Showing 10 of 567 papers
Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, and Anaphylaxis.
High-flow nasal Oxygen with or without alternating helmet Non-invasive ventilation for Oxygenation sUpport in acute Respiratory failure (HONOUR): a protocol for a pilot randomised controlled trial
IntroductionAcute hypoxaemic respiratory failure is a common reason for intensive care unit (ICU) admission. Non-invasive respiratory support strategies such as high-flow nasal oxygen (HFNO) and helmet non-invasive ventilation may reduce the need for invasive mechanical ventilation and death. The High-flow nasal Oxygen with or without alternating helmet Non-invasive ventilation for Oxygenation sUpport in acute Respiratory failure pilot trial is designed to compare helmet non-invasive ventilation combined with HFNO vs HFNO alone in patients with acute hypoxaemic respiratory failure and to determine the feasibility of a larger randomised controlled trial.Methods and analysisThis is a pragmatic, open-label, multicentre randomised controlled pilot trial enrolling 200 critically ill adults with acute hypoxaemic respiratory failure across 12 Canadian ICUs. Participants are randomised 1 to 1 to receive either helmet non-invasive ventilation plus HFNO or HFNO alone for at least 48 hours. The primary aim is to assess feasibility metrics including recruitment rate, protocol adherence and fidelity to pre-specified intubation criteria. Secondary outcomes include rates of intubation, all-cause mortality, ventilator-free days, ICU length of stay and quality of life at 6 months. Primary and secondary outcomes will be analysed using Bayesian methods.Ethics and disseminationEthics approval has been obtained at all participating centres. Findings will inform the feasibility and design of a future full-scale trial and be disseminated through peer review publications and conference presentations.Trial registration numberClinicalTrials.gov Identifier: NCT05078034.
Read moreDevelopmental Epileptic Encephalopathy in a Pediatric Patient: Insights from a Novel SULT4A1 Variant and Genetic Challenges.
Developmental epileptic encephalopathy (DEE) in children presents significant diagnostic and management challenges. Advances in whole-exome sequencing (WES) have enabled the identification of rare genetic variants, offering new insights into these complex conditions. Here, we report a 2.5-year-old girl with refractory epilepsy and DEE, in whom WES revealed a novel homozygous SULT4A1 splice-site variant. Although the SULT4A1 variant likely contributed to her condition, the later emergence of motor and speech delay in a sibling with the same mutation suggests variable expressivity or age-dependent onset, rather than incomplete penetrance. The patient partially responded to immunotherapy but continued to experience breakthrough seizures and developmental delays, highlighting the challenges in managing such disorders. This case underscores the importance of genetic testing, functional studies, and genetic counseling in the diagnosis and treatment of rare neurodevelopmental disorders.
Read moreCharacterizing the symptomatology and pathophysiology of allergic rhinitis using a nasal allergen challenge model – a subset of the allergic rhinitis microbiome study
BackgroundSince 2015, our nasal allergen challenge (NAC) protocol has been used to investigate the pathophysiology of allergic rhinitis (AR) with various allergens. However, we have yet to publish a comprehensive examination of the pathophysiology associated with AR to ragweed pollen.MethodsNineteen ragweed pollen allergic and 12 healthy (nonallergic) control participants from Kingston, Ontario, Canada, completed the NAC to ragweed pollen extract out-of-season. Total nasal symptom score (TNSS) and percent fall in peak nasal inspiratory flow (PNIF) were collected up to 48 h post-exposure. Nasal fluid and serum samples were collected post-exposure, and white blood cell differential counts, serum ragweed-specific and total immunoglobulin-E (IgE), and nasal cytokine concentrations were analyzed. Statistical tests were performed using GraphPad Prism 10.4.0.ResultsThe mean TNSS and percent PNIF fall from baseline were significantly higher in participants with ragweed pollen allergy compared to nonallergic controls up to 24 h (P ≤ 0.05) and 12 h (P ≤ 0.05) post-NAC, respectively. Nasal eosinophils significantly increased in allergic participants at 6 h (P = 0.0010) and 24 h (P = 0.0049), while peripheral blood eosinophil percentages decreased significantly at 6 h compared to baseline (P = 0.0499). The specific to total IgE ratio for allergic participants significantly increased 1 h and 24 h (P = 0.0022 and P = 0.0034, respectively) post-NAC, with a decrease at 6 h compared to both 1 h and 24 h (P = 0.0224 and P = 0.0316, respectively). Allergic and nonallergic participants had significantly different cytokine profiles, particularly IL-4, IL-5, IL-6, IL-13, MIP-1β, and TNF-α.ConclusionsThis study confirms the effectiveness of our NAC protocol in eliciting clinical and biological responses in ragweed-allergic participants, particularly highlighting eosinophil activity, IgE, and cytokine dynamics. Future research should investigate the roles of specific IgE, IL-4, and eosinophil activation in allergic inflammation. Additionally, this NAC study population provides a strong foundation for examining the nasal microbiome in AR. Longitudinal studies exploring the relationship between allergic responses and microbiome shifts could offer deeper insights into the underlying mechanisms of disease.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13223-025-00980-5.
Read moreFibrilación Auricular en la Práctica Clínica
Adherence of published randomized phase 3 cancer trials to principles proposed by common-sense oncology.
11019 Background: Randomized clinical trials (RCTs) remain the gold standard for evaluating the efficacy and safety of novel cancer therapies. Some RCTs are well-designed and show meaningful improvements in patient outcomes while others are confounded by various types of bias, or do not reflect outcomes that matter to patients. Published RCTs should be designed, analyzed and reported to provide optimal, unbiased information for clinicians to enhance treatment decision-making Common-Sense Oncology (CSO) is an initiative of clinicians, patient advocates, researchers, and policymakers with the mission of ensuring that cancer care and research are focused on outcomes that matter to patients. CSO has published a checklist for the design, analysis and reporting of RCTs evaluating systemic treatments for cancer. In the present study, we have applied the checklists to a cohort of cancer drug trials to assess the extent to which CSO principles were incorporated in reports of RCTs published in 2023 in high-impact journals. Methods: We reviewed retrospectively phase 3 RCTs evaluating systemic therapies for adult solid tumors published in 2023 in The New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, and Annals of Oncology . These journals were selected based on their high impact. For each trial we evaluated the trial design in the methodology, how the results were reported and the discussion section using the CSO RCT Checklist. Results: 50 RCTs evaluating systemic therapies for solid tumors were published in 2023. The most common tumor types were lung, liver, and prostate cancer. Progression-free survival and overall survival were the primary endpoints in 44% (22) and 42% (21) of trials, respectively. Only 36/50 trials justified the control arm, 25/50 justified the primary endpoint, and 18 included Quality-of-Life as a secondary endpoint. Only two trials addressed strategies to limit censoring and dropout; numbers of censored patients (with numbers at risk) were shown under Kaplan-Meier curves in only 21/50 trials, and sensitivity analysis to determine the potential effects of censoring was done in only 5 trials. Chronic toxicities were reported in only one trial, only 7 trials included patient-reported outcomes and only 3/50 trials mentioned cost of the drug. Conclusions: Our findings underscore the need for standardized methodologies, comprehensive design, and reporting in oncology RCTs. By identifying gaps in RCT design and reporting, CSO aims to improve the quality and consistency of future trials.
Read moreEndoscopic Treatment of Achalasia
Background: Achalasia is the most common major esophageal motility disorder, characterized by impaired lower esophageal sphincter relaxation and absent or ineffective peristalsis. Peroral endoscopic myotomy (POEM), pneumatic dilation, and botulinum toxin injection are the main endoscopic therapies available. This review highlights recent advances, technical variations, and updated evidence on the efficacy and safety of POEM. Summary: POEM has emerged as a highly effective and minimally invasive treatment for achalasia, with randomized controlled trials demonstrating excellent long-term clinical success and durability. Its safety profile and capacity for a tailored myotomy offer distinct advantages over alternative therapies. However, gastroesophageal reflux disease (GERD) remains a key concern. Ongoing efforts are focused on optimizing procedural techniques, including myotomy length and orientation, sling fiber preservation, and the addition of fundoplication. Additionally, training protocols, patient selection criteria, and strategies to prevent and predict GERD are critical areas of development. Future research should aim to refine follow-up strategies and define objective measures of success to enhance the safety, efficacy, and accessibility of POEM. Key Messages: Endoscopic treatments of achalasia, particularly POEM, offer effective and durable outcomes. Optimizing technique, refining training, and managing GERD are essential for improving safety and long-term success.
Read more211 Three-Dimensional Navigated Mass Spectrometry for Intraoperative Margin Assessment During Breast Cancer Surgery
Editors’ Choice
External Validation of Brief Resolved Unexplained Events Prediction Rules for Serious Underlying Diagnosis
The American Academy of Pediatrics (AAP) higher-risk criteria for brief resolved unexplained events (BRUE) have a low positive predictive value (4.8%) and misclassify most infants as higher risk (>90%). New BRUE prediction rules from a US cohort of 3283 infants showed improved discrimination; however, these rules have not been validated in an external cohort. To externally validate new BRUE prediction rules and compare them with the AAP higher-risk criteria. This was a retrospective multicenter cohort study conducted from 2017 to 2021 and monitored for 90 days after index presentation. The setting included infants younger than 1 year with a BRUE identified through retrospective chart review from 11 Canadian hospitals. Study data were analyzed from March 2022 to March 2024. The BRUE prediction rules. The primary outcome was a serious underlying diagnosis, defined as conditions where a delay in diagnosis could lead to increased morbidity or mortality. Of 1042 patients (median [IQR] age, 41 [13-84] days; 529 female [50.8%]), 977 (93.8%) were classified as higher risk by the AAP criteria. A total of 79 patients (7.6%) had a serious underlying diagnosis. For this outcome, the AAP criteria demonstrated a sensitivity of 100.0% (95% CI, 95.4%-100.0%), a specificity of 6.7% (95% CI, 5.2%-8.5%), a positive likelihood ratio (LR+) of 1.07 (95% CI, 1.05-1.09), and an AUC of 0.53 (95% CI, 0.53-0.54). The BRUE prediction rule for discerning serious diagnoses displayed an AUC of 0.60 (95% CI, 0.54-0.67; calibration intercept: 0.60), which improved to an AUC of 0.71 (95% CI, 0.65-0.76; P < .001; calibration intercept: 0.00) after model revision. Event recurrence was noted in 163 patients (15.6%). For this outcome, the AAP criteria yielded a sensitivity of 99.4% (95% CI, 96.6%-100.0%), a specificity of 7.3% (95% CI, 5.7%-9.2%), an LR+ of 1.07 (95% CI, 1.05-1.10), and an AUC of 0.58 (95% CI, 0.56-0.58). The AUC of the prediction rule stood at 0.67 (95% CI, 0.62-0.72; calibration intercept: 0.15). Results of this multicenter cohort study show that the BRUE prediction rules outperformed the AAP higher-risk criteria on external geographical validation, and performance improved after recalibration. These rules provide clinicians and families with a more precise tool to support decision-making, grounded in individual risk tolerance.
Read more